Somatostatin Receptors (Somatostatin Receptor)

Cell surface proteins that bind somatostatin and trigger intracellular changes which influence the behavior of cells. Somatostatin is a hypothalamic hormone, a pancreatic hormone, and a central and peripheral neurotransmitter. Activated somatostatin receptors on pituitary cells inhibit the release of growth hormone; those on endocrine and gastrointestinal cells regulate the absorption and utilization of nutrients; and those on neurons mediate somatostatin's role as a neurotransmitter.

Also Known As:

Networked: 2023 relevant articles (97 outcomes, 257 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Reubi, Jean Claude: 35 articles (04/2015 - 05/2002)
2.	Krenning, Eric P: 33 articles (08/2014 - 04/2002)
3.	de Jong, Marion: 25 articles (05/2015 - 04/2003)
4.	Schulz, Stefan: 20 articles (09/2015 - 03/2002)
5.	Waser, Beatrice: 20 articles (04/2015 - 12/2002)
6.	Kwekkeboom, Dik J: 19 articles (12/2015 - 04/2002)
7.	Maecke, Helmut R: 19 articles (02/2015 - 02/2002)
8.	Hofland, Leo J: 19 articles (01/2014 - 12/2002)
9.	de Herder, Wouter W: 16 articles (01/2015 - 12/2002)
10.	Culler, M D: 15 articles (05/2008 - 02/2000)

Related Diseases

1.	Neoplasms (Cancer) 12/01/2013 - "Drugs targeting the somatostatin receptor are beneficial in these tumors. " 08/20/2013 - "By using this GO-based fluorescent platform, we can detect AOC with a low detection limit of 2 ng/mL. As a step further, we employ this GO-FOC biosensor to image somatostatin receptor subtype 2 overexpressed AR42J tumor cells, which demonstrates high promise for molecular imaging in cancer diagnosis. " 09/01/2008 - "After the discovery of somatostatin receptors (SSTR) over-expression in this group of neoplasms, NET management has significantly improved. " 07/01/2014 - "Gallium-68 (Ga-68) DOTA-peptide positron emission tomography/computer tomography (PET/CT) has higher sensitivity and improved spatial resolution for the detection of somatostatin receptor expressing tumors than conventional somatostatin receptor scintigraphy. " 09/06/2007 - "Despite the differences in biological efficacy, the favorable binding affinity, tumor uptake, and tumor-to-background ratio results for both diastereomeric species predict that both are effective for imaging somatostatin receptor-positive tumors in vivo."
2.	Neoplasm Metastasis (Metastasis) 01/01/2007 - "Predictive factors for tumour remission were high tumour uptake on somatostatin receptor scintigraphy and limited amount of liver metastases. " 04/20/2005 - "Higher remission rates were positively correlated with high uptake on pretherapy somatostatin receptor imaging and a limited number of liver metastases, whereas PD was significantly more frequent in patients with a low performance score and extensive disease. " 10/01/2006 - "Somatostatin receptor scintigraphy (SRS) holds great promise for detecting primary tumours and metastases. " 10/01/2014 - "The aim of this study was to define the frequency of neuroendocrine neoplasia (NEN) metastasis sites based on the primary lesion and create a database of SUVmax as a marker of human SSTR (somatostatin receptors) expression by semiquantitative analysis in vivo Ga DOTATATE PET/CT. " 10/01/1999 - "The aim of this study was to compare prospectively somatostatin receptor scintigraphy (SRS) using 111n-pentetreotide with bone scintigraphy using 99mTc-hydroxymethylene diphosphonate for the detection of bone metastases. "
3.	Neuroendocrine Tumors (Neuroendocrine Tumor) 02/01/2010 - "Aim of this study was to evaluate the feasibility, the efficacy and the toxicity of this treatment in neuroendocrine tumors expressing somatostatin receptors relapsed or refractory to conventional therapies. " 11/01/2007 - "A multicentric study was designed to compare somatostatin receptor immunohistochemical expression with in vivo scintigraphic data and verify its usefulness in the clinical management of neuroendocrine tumors. " 09/01/2006 - "The aim of the study was to provide dosimetric data on intrahepatic (111)In-diethylenetriaminepentaacetic acid (DTPA)-D-Phe(1)-octreotide therapy for neuroendocrine tumors with overexpression of somatostatin receptors. " 01/01/2003 - "Many studies describe the sensitivities and specificities of computed tomography (CT), magnetic resonance imaging (MRI), and somatostatin receptor scintigraphy (SRS) in patients with gastrointestinal neuroendocrine tumors (GNT). " 05/01/1994 - "In this study 76 patients with immunohistologically proven neuroendocrine tumors were analysed by comparing somatostatin-receptor scintigraphy with conventional imaging techniques. "
4.	Carcinoid Tumor (Carcinoid) 08/01/2002 - "We performed this study in order to evaluate the diagnostic accuracy of whole-body fluorodeoxyglucose positron emission tomography (FDG PET) imaging and somatostatin receptor scintigraphy (SRS) for localizing primary carcinoid tumours and evaluating the extent of the disease. " 02/01/2001 - "This human transplantable carcinoid tumor, designated GOT1, grafted to nude mice, will give unique possibilities for studies of somatostatin receptor- and VMAT-mediated radionuclide uptake as well as for studies of secretory mechanisms." 12/01/2015 - "Somatostatin receptor PET/CT in restaging of typical and atypical lung carcinoids." 11/01/2015 - "This case report and review of the literature suggests that minute rectal carcinoids are at risk of metastasizing and that these patients should be investigated for lymph node and distant metastatic spread with CT and somatostatin receptor scintigraphy or its equivalent, as this would influence prognosis and surgical management of these patients. " 07/01/2015 - "We evaluated somatostatin receptor scintigraphy (SRS) with (111)In-pentetreotide incremental value in pulmonary carcinoid (PC) diagnosis compared to contrast enhanced Computed Tomography (ceCT). "
5.	Gastrinoma 01/01/2006 - "We overviewed the recent development of curative surgery for gastrinoma that has been rapidly improved since the development of new localization techniques, especially the selective arterial secretagogue injection test (SASI test) and somatostatin receptor scintigraphy (SRS). " 04/01/2002 - "Endoscopic ultrasonography and somatostatin receptor scintigraphy are the gold standard for localization of gastrinomas. " 10/01/1999 - "1: somatostatin receptor scintigraphy is the most sensitive modality for detection of primary or metastatic gastrinomas; Study n. " 12/01/2011 - "Somatostatin receptor scintigraphy (SRS) is a valuable method for the detection of somatostatin receptor-positive lesions like gastrinoma. " 06/01/2005 - "EUS in conjunction with Somatostatin Receptor Scanning (SRS) has a combined sensitivity of 93% for gastrinomas. "

Related Drugs and Biologics

1.	Somatostatin (Somatotropin Release-Inhibiting Factor)
2.	Octreotide (Sandostatin)
3.	Peptide Receptors (Peptide Receptor)
4.	lanreotide (Somatuline)
5.	pentetreotide (OctreoScan)
6.	pasireotide
7.	(DOTA(0)-Phe(1)-Tyr(3))octreotide (SMT 487)
8.	Hormones
9.	Messenger RNA (mRNA)
10.	Pentetic Acid (DTPA)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Radiotherapy
3.	Heterologous Transplantation (Xenotransplantation)
4.	Palliative Care (Palliative Medicine)
5.	Aftercare (After-Treatment)